Skip to main content

Research Repository

Advanced Search

Time-evolved metrics for safety pharmacological assessments of small molecules and biologics.

Srinivasan, Bharath

Authors

Bharath Srinivasan



Abstract

Safety of a small-molecule drug is oftentimes a more important criterion than efficacy in determining drug approval. Aspects of safety pharmacological and toxicological liabilities, often resulting from dose-dependent undesirable interaction with either the primary target of interest or secondary targets, have a huge role to play in determining 'first-in-human' dosage and phase I clinical trials. Given the open thermodynamic nature of the human subjects, it is mandatory that kinetics of drug-target and drug-off-target interactions govern the way selectivity margins are assessed, and dose is decided. However, lack of sufficient thrust on kinetics in guiding early drug discovery decisions has resulted in an overreliance on IC50 measure (a proxy for thermodynamic Ki) as a means of computing safety across the target of interest and potential off-targets. Moreover, based on established practises and known weight of evidence of targets with safety adverse events, the primary panel of secondary pharmacology targets are biased with greater preference for G-protein coupled receptors, transporters and ion-channels with a paucity of enzymes. This can pose unique challenges in assessing safety, especially for advancing and emergent modalities. In this perspective, the critical role kinetic margins should play in assessing safety is emphasised given the myriad assay conditions that can modulate the equilibrium thermodynamic measure as embodied in the proxy report of IC50. Further, it advocates selective and judicious expansion of primary safety panels with greater representation of enzymes and reduced redundancy in eventual read-outs based on potential for correlative output among the off-target classes assessed.

Citation

SRINIVASAN, B. 2025. Time-evolved metrics for safety pharmacological assessments of small molecules and biologics. British journal of pharmacology [online], 182(13), pages 2831-2841. Available from: https://doi.org/10.1111/bph.70064

Journal Article Type Review
Acceptance Date Mar 21, 2025
Online Publication Date Apr 27, 2025
Publication Date Jul 31, 2025
Deposit Date May 9, 2025
Publicly Available Date Apr 28, 2026
Journal British journal of pharmacology
Print ISSN 0007-1188
Electronic ISSN 1476-5381
Publisher Wiley
Peer Reviewed Peer Reviewed
Volume 182
Issue 13
Pages 2831-2841
DOI https://doi.org/10.1111/bph.70064
Keywords Emerging modalities; Equilibrium; Irreversible; Kinetics; Non-equilibrium; Primary pharmacology; Safety pharmacology; Secondary pharmacology; Slow-onset
Public URL https://rgu-repository.worktribe.com/output/2830403

Files

This file is under embargo until Apr 28, 2026 due to copyright reasons.

Contact publications@rgu.ac.uk to request a copy for personal use.



Downloadable Citations